The US FDA is putting off a decision on the scope of its final rule regarding the evidence the agency considers in determining how a manufacturer intends its product to be used. However, the agency seems to agree with industry that the rule needs to be revised to make it clear certain communications will not expose companies to potential liability.
In January, the agency announced a proposal to delay implementation of amendments to the medical product "intended use" regulations for...